<DOC>
	<DOCNO>NCT02536339</DOCNO>
	<brief_summary>This study examine safety efficacy pertuzumab combination high-dose trastuzumab adult participant HER2-positive MBC CNS metastases disease progression brain follow radiotherapy .</brief_summary>
	<brief_title>Pertuzumab With High-Dose Trastuzumab Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Metastatic Breast Cancer ( MBC ) With Central Nervous System ( CNS ) Progression Post-Radiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adults least 18 year age Pathologically confirm HER2positive MBC Progression new brain metastasis completion wholebrain radiotherapy stereotactic radiosurgery Completion wholebrain radiotherapy stereotactic radiosurgery 60 day prior enrollment Stable systemic disease Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Left ventricular ejection fraction ( LVEF ) least 50 % Adequate hematologic , renal , hepatic function Life expectancy 12 week Progression systemic disease Screening Leptomeningeal disease History intolerance hypersensitivity study drug Use certain investigational therapy within 21 day prior enrollment Current anthracycline use Unwillingness discontinue adotrastuzumab emtansine lapatinib use Active infection Pregnant lactate woman Significant history risk cardiac disease Symptomatic intrinsic lung disease lung involvement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>